Dr Reddy’s cancels deal with JB chemicals

27 Sep 2011 Evaluate

Dr Reddy’s Laboratories (DRL) called off a deal to acquire the prescription portfolio of JB Chemicals and Pharmaceuticals in Russia owing to differences over valuation and other operational issues. Earlier in July, Dr Reddy’s Laboratories had entered in to an agreement with the Mumbai-based pharmaceutical firm to acquire 20 key prescription brands marketed by JB Chemicals in Russia and Common Wealth of Independent States (CIS) regions. The transaction involved sale of product registrations and intellectual property rights for a consideration of $35 million. The acquisition was supposed to expand Dr Reddy’s prescription, hospital and over the-counter market portfolio.

Dr. Reddys Lab Share Price

6080.25 -14.85 (-0.24%)
14-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.00
Dr. Reddys Lab 6080.25
Cipla 1565.50
Zydus Lifesciences 1110.95
Lupin 1601.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.